Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease

Background: Alzheimer’s disease (AD) is the most common cause of dementia in older patients. Rivastigmine (RV, Exelon, Novartis), a reversible cholinesterase inhibitor, improves clinical manifestations of AD and may enhance ACh-modulated electroencephalogram (EEG) alpha frequency. This pilot study a...

Full description

Bibliographic Details
Main Authors: Moretti, Davide V., Frisoni, Giovanni B., Binetti, Giuliano, Zanetti, Orazio
Format: Online
Language:English
Published: Frontiers Media S.A. 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107674/
id pubmed-4107674
recordtype oai_dc
spelling pubmed-41076742014-08-06 Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease Moretti, Davide V. Frisoni, Giovanni B. Binetti, Giuliano Zanetti, Orazio Neuroscience Background: Alzheimer’s disease (AD) is the most common cause of dementia in older patients. Rivastigmine (RV, Exelon, Novartis), a reversible cholinesterase inhibitor, improves clinical manifestations of AD and may enhance ACh-modulated electroencephalogram (EEG) alpha frequency. This pilot study aimed to determine the effects of two formulations of RV [transdermal patch (RV-TDP) and oral capsules (TV-CP)] on alpha frequency, in particular the posterior dominant rhythm, and cognitive function [assessed by the Mini-Mental State Examination (MMSE)] in patients with AD. Frontiers Media S.A. 2014-07-23 /pmc/articles/PMC4107674/ /pubmed/25100996 http://dx.doi.org/10.3389/fnagi.2014.00179 Text en Copyright © 2014 Moretti, Frisoni, Binetti and Zanetti. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Moretti, Davide V.
Frisoni, Giovanni B.
Binetti, Giuliano
Zanetti, Orazio
spellingShingle Moretti, Davide V.
Frisoni, Giovanni B.
Binetti, Giuliano
Zanetti, Orazio
Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
author_facet Moretti, Davide V.
Frisoni, Giovanni B.
Binetti, Giuliano
Zanetti, Orazio
author_sort Moretti, Davide V.
title Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
title_short Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
title_full Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
title_fullStr Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
title_full_unstemmed Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
title_sort comparison of the effects of transdermal and oral rivastigmine on cognitive function and eeg markers in patients with alzheimer’s disease
description Background: Alzheimer’s disease (AD) is the most common cause of dementia in older patients. Rivastigmine (RV, Exelon, Novartis), a reversible cholinesterase inhibitor, improves clinical manifestations of AD and may enhance ACh-modulated electroencephalogram (EEG) alpha frequency. This pilot study aimed to determine the effects of two formulations of RV [transdermal patch (RV-TDP) and oral capsules (TV-CP)] on alpha frequency, in particular the posterior dominant rhythm, and cognitive function [assessed by the Mini-Mental State Examination (MMSE)] in patients with AD.
publisher Frontiers Media S.A.
publishDate 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107674/
_version_ 1613116863399591936

Similar Items